Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic Anti-cd40 ligand antibodies

An antibody and antigen technology, applied in the direction of antibody, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, allergic diseases, etc.

Pending Publication Date: 2020-01-07
ALS THERAPY DEV INST
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No anti-CD40L antibody is commercially available, although anti-CD40L antibody hu5c8 shows efficacy in human patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic Anti-cd40 ligand antibodies
  • Therapeutic Anti-cd40 ligand antibodies
  • Therapeutic Anti-cd40 ligand antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0073] All embodiments of the isolated antibodies or antigen-binding fragments thereof bind CD40L and inhibit or block the binding of CD40L to CD40. As used herein, "blocking the binding of CD40L and CD40" and "blocking the interaction between CD40L and CD40" are used interchangeably. Inhibiting or blocking binding can be direct or indirect. In general, the antibody or antigen-binding fragment thereof will compete specifically with CD40 for the same binding site on CD40L, or through steric positioning caused by binding of the antibody or antigen-binding fragment thereof near the CD40-binding site of CD40L. Block to physically interfere with the binding of CD40L to CD40. In other cases, the effect is indirect, eg, the antibody or antigen-binding fragment thereof causes an allosteric change in the conformation of CD40L, thereby inhibiting or eliminating its binding to CD40.

[0074]One embodiment is an isolated antibody that binds CD40L and comprises a light chain and a heavy ...

Embodiment 1

[0152] Example 1 CD40L binding assay

[0153] To compare CD40L binding of antibodies from all 16 clones relative to 5c8 or AT-1501, binding assays were performed using 2 clones, with 5c8 and AT-1501 run on the same 96-well assay plate. A three-part sandwich ELISA assay was used to determine the level of binding of the disclosed antibodies compared to reference antibodies 5c8-19 and AT1501. A 96-well polystyrene plate was coated with recombinant human CD40L in PBS (BioLegend cat# 591706) using 2ug / ml, and 50ul / well was added to a Costar 96-well half-area high binding assay plate (Corning 3690) and Incubate overnight at 4 °C. Plates were blocked with (1X) PBS / 1.0% BSA (140ul / well) for 1 hour at room temperature to prevent background binding. Add 5C8 or AT1501 (starting from 2ug / ml, serial 2-fold dilution) (50ul / well) for binding curve and incubate at room temperature for 1 hour. Plates were washed and incubated with 1:10,000 dilution of HRP-(Fab2) donkey anti-human IgG antibo...

Embodiment 2

[0161] Example 2 Binding activity to human FcγRI, FcγRIIa, FcγRIIIa and FcγRIIIb

[0162] Sixteen VH / VL antibody clones were constructed using IgGl Fc (SEQ ID NO: 21 ) with two mutations, P238S and N297G. These antibody clones were assayed for Fc effector function against binding to human FcyRI, FcyRIIa and FcyRIIIa.

[0163] Anti-CD40L antibody (abatacept included as negative control) was diluted to 2ug / ml in (1X) PBS, and 50ul / well was added to Costar 96-well half-area high binding assay plate (Corning 3690) for 4 Incubate overnight at °C. Plates were blocked with (1X) PBS / 1.0% BSA (140ul / well) for 1 hour at room temperature to prevent background binding. Recombinant human FcγRI, FcγIIa, FcγIIIa and FcγIIIb (serial 2-fold dilutions starting from 5ug / ml) (50ul / well) for binding curves were added and incubated at room temperature for 1 hour. Plates were washed and incubated with 2ug / ml mouse anti-human CD16 (anti-FcRIII), CD32 (anti-FcRIIa) or CD64 (anti-FcRI) antibodies (e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Anti-CD40L antibodies and antigen binding fragments thereof, compositions comprising the antibodies or antigen binding fragments, Anti-CD40L antibodies with reduced effector function, and method of using same for treatment of CD40L-related diseases or disorders.

Description

[0001] Cross References to Related Applications [0002] This PCT application claims the benefit of U.S. Provisional Application No. 62 / 510,471, filed May 24, 2017, the disclosure of which is hereby incorporated by reference in its entirety. [0003] sequence listing [0004] This application incorporates by reference in its entirety the sequence listing named "224823-431206_ST25.txt" created at 2:40 pm on May 23, 2018, which is 100 KB and electronically filed with this document. technical field [0005] Anti-CD40L antibodies, compositions comprising the same, and methods of using them to treat CD40L-associated diseases or disorders. Background technique [0006] The interaction of CD40 with its ligand CD40L plays a key role in regulating the immune response. Binding of CD40L to CD40 triggers activation of the CD40 pathway, which upregulates costimulatory molecules such as CD80 and CD86. Blockade of the interaction between CD40 and CD40L by monoclonal antibodies has been ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28
CPCC07K16/2875C07K2317/24C07K2317/40C07K2317/41C07K2317/76C07K2317/52A61K39/395C07K2317/565A61P37/00
Inventor A·卢戈维斯科
Owner ALS THERAPY DEV INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com